XXXX group V: an analysis of prognostic factors.

@entity1 @entity5 @entity66 @entity995
A retrospective analysis of the University of Minnesota (Minneapolis) experience with @entity995 is presented. Seventy-five @entity1 were diagnosed with @entity995 between 1958 and 1983, of which 53 (71%) had at least one Reese-Ellsworth group V eye. Nineteen group V @entity1 and one group II @entity1 developed @entity66 recurrence. The cumulative actuarial rate of recurrence at 12 years was 36% for @entity1 with group V disease. The median time from diagnosis to recurrence for unilateral @entity1 was seven months and for bilateral @entity1 28 months (P = .001). @entity1 developing @entity66 had a 10-year actuarial survival rate postrecurrence of 34%. The four long-term survivors of extraocular recurrences had had isolated orbital or local soft tissue recurrences only. Features of group V @entity1 associated with extraocular recurrences were identified by univariate life table analyses. Clinical poor-risk factors included the nongenetic form of the disease (P = .03) and male sex (P = .02). Pathologic poor risk factors included rubeosis (P = .01), undifferentiated histology (P = .03), large @entity5 size (P = .05), and intraocular extension to the anterior segment (P = .02), retinal pigment epithelium (P = .03), choroid (P less than .001), and optic nerve beyond the lamina cribrosa (P = .02). Treatment-associated poor-risk factors included an optic nerve length of less than 5 mm removed at enucleation (P = .003). Multivariate life table analyses demonstrated the following parameters to be independent poor-prognostic factors: optic nerve length of less than 5 mm removed at enucleation (P = .001), optic nerve involvement (P = .004), and large @entity5 size (P = .01). These results will help to identify @entity1 with @entity995 who are at greatest risk for extraocular recurrence.
